Evommune, Inc. (EVMN)
NYSEHealth CareBiotechnologySnapshot 2026-11-05
$6.37+5.46%
Close 2026-11-05 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · EVMN
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine…
Stated in 2 of 2 supplied quarters. Management reported: “Second Quarter 2026 Financial Results • Cash, Cash Equivalents and Investments: As of June 30, 2026, the Company had cash, cash equivalents and investments of $288.0 million, compared to $216.7 million as of December 31, 2025.” “With a strong balance sheet supporting operations into 2029, we remain focused on advancing a portfolio of programs with the stated goal of broadly addressing chronic inflammatory diseases.””
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine…”
““With a strong cash position expected to support our operations through 2028, we believe we are well positioned to execute on key milestones and further advance our pipeline of therapies addressing i…”
Manufacturing is ongoing and following completion of standard scale-up and toxicology activities, the trial is anticipated to begin in mid-2027.
Stated in 2 of 2 supplied quarters. Management reported: “• Phase 2b AD Trial to Initiate in mid-2027: The planned Phase 2b, placebo-controlled, dose-ranging clinical trial is expected to include at least three subcutaneous dosing regimens of EVO301 tested over a 16-week treatment period.” ““We continue to work towards bringing meaningful clinical benefit to AD patients, and importantly, EVO301, our IL-18BP fusion protein, which recently generated positive Phase 2a proof-of-concept data, will enter a Phase 2b trial planned for mid-2027.”
“Manufacturing is ongoing and following completion of standard scale-up and toxicology activities, the trial is anticipated to begin in mid-2027.”
“The planned Phase 2b, placebo-controlled, dose-ranging clinical trial is expected to include at least three dosing regimens of EVO301 tested over a 16-week treatment period, with a planned trial star…”
• Migraine Prophylaxis Phase 2b Trial Now Underway with Top-Line Data Anticipated in 2027: In July 2026 , the Company initiated a global randomized, double-blind, placebo-controlled Phase 2b dose-ran…
Stated in 2 of 2 supplied quarters. Management reported: “• Migraine Prophylaxis Phase 2b Trial Now Underway with Top-Line Data Anticipated in 2027: In July 2026 , the Company initiated a global randomized, double-blind, placebo-controlled Phase 2b dose-ranging clinical trial in migraine prophylaxis.” ““EVO756 was generally well tolerated with a safety profile consistent with prior studies, supporting its continued evaluation in migraine prophylaxis.”
“• Migraine Prophylaxis Phase 2b Trial Now Underway with Top-Line Data Anticipated in 2027: In July 2026 , the Company initiated a global randomized, double-blind, placebo-controlled Phase 2b dose-ran…”
“We also expect to initiate a Phase 2b clinical trial in a third indication, migraine prophylaxis, in mid-2026, where we believe the biology and opportunity are both very compelling.”
Evommune previously announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals Inc. (SSE: 688302) granting Evommune worldwide rights outside of Greater China to develop,…
Stated in a supplied disclosure. Management reported: “Evommune previously announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals Inc. (SSE: 688302) granting Evommune worldwide rights outside of Greater China to develop, manufacture and commercialize EVO570 (formerly HC118 and known as HP570 in Greater China), an oral VAV1-directed molecular glue degrader (MGD).” “Management will cover the biology of VAV1, EVO570’s preclinical profile, the planned development path in rheumatoid arthritis, the terms of the transaction and how EVO570 fits within the Company’s broader immunology pipeline.”
Complete and report Phase 2b clinical trial data for EVO756 in atopic dermatitis and migraine prophylaxis, focusing on efficacy and safety.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
6 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.